Risk factors for cytomegalovirus retinitis following bone marrow transplantation from unrelated donors in patients with severe aplastic anemia or myelodysplasia

International Journal of Hematology

Volumn 74, Issue 4, 2001, Pages 455-460

  Kuriyama, Kikuko ^a   Todo, Shinjiro ^a   Ikushima, Satoshi ^a   Fujii, Noriko ^a,b   Yoshihara, Takao ^b   Tsunamoto, Kentaro ^b   Naya, Mayumi ^c   Hojo, Makoto ^c   Hibi, Shigeyoshi ^a   Morimoto, Akira ^a   Imashuku, Shinsaku ^d  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^c KYOTO CITY HOSPITAL   (Japan)

^d Kyoto City Institute of Health and Environmental Sciences   (Japan)

Author keywords

Antithymocyte globulin; Cytomegalovirus retinitis; Hypoplastic myelodysplastic syndrome; Severe aplastic anemia; Unrelated bone marrow transplantation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE CONTROL STUDY; CASE REPORT; DONOR; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELODYSPLASTIC SYNDROME; RETINITIS; RISK FACTOR;

ADOLESCENT; ANEMIA, APLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS RETINITIS; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 0035756685     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982092     Document Type: Article

References (29)

1. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997; 79:1548-1551.
2. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699-705.
3. Geary CG, Harrison CJ, Philpott NJ, Hows JM, Gordon-Smith EC, Marsh JC. Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy. Br J Haematol. 1999;104:271-274.
4. Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anemia. Br J Haematol. 1998;100:393-400.
5. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5:243-252.
6. Gillio AP, Boulad F, Small TN, et al. Comparison of long-term outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. Biol Blood Marrow Transplant. 1997;3:18-24.
7. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party. Blood. 1999;93:2191-2195.
8. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosprine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood. 2000;95:1931-1934.
9. Matloub YH, Smith C, Bostrom B, et al. One course versus two courses of antithymocyte globulin for the treatment of severe aplastic anemia in children. J Pediatr Hematol Oncol. 1997;19: 110-114.
10. Davies SM, Wagner JE, Defor T, et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br J Haematol. 1997;96:749-756.
11. Margolis D, Camitta B, Pietryga D, et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol. 1996;94:65-72.
12. Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol. 2000;37:43-55.
13. Kojima S, Inaba J, Kondo M, et al. Unrelated donor marrow transplantation for severe acquired aplastic anemia using cyclophosphamide, antithmyocyte globulin, and total body irradiation. Blood. 1995;85:291-292.
14. Matsuda Y, Hara J, Osugi Y, et al. Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors. Bone Marrow Transplant. 1998;21:355-360.
15. Okamoto T, Okada M, Mori A, et al. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in myelosuppressed unrelated bone marrow transplant patient. Bone Marrow Transplant. 1997;20:801-803.
16. Ratnamohan VM, Chapman J, Howse H, et al. Cytomegalovirus and herpesvirus 6 both cause viral disease after renal transplantation. Transplantation. 1998;66:877-882
17. Zaia JA. Cytomegalovirus infection. In: Foeman SJ, ed. Bone Marrow Transplantation. Boston, MA: Blackwell; 1994:376-403.
18. Micallef IN, Chhanabhai M,Gascoyne RD,et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant. 1998;22: 981-987.
19. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorder after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
20. Kurihara T, Hayashi J, Matsuoka T, et al. HCMV pp65 antigenemia assay using indirect alkaline phosphatase staining method. Biomed Res. 1995;16:125-129.
21. Imashuku S, Hibi S, Sako M, et al. Heterogeneity of immune markers in hemophagocytic lymphohistiocytosis: comparative study of 9 familial and 14 familial inheritance-unproved cases. J Pediatr Hematol Oncol. 1998;20:207-214.
22. Takanashi M, Kadono Y, Tabata Y, Hibi S. Successful immunosuppressive therapy for a patient with hypoplastic myelodysplastic syndrome. Jpn J Clin Hematol. 1999;40:1093-1099.
23. Coskuncan NM, Jabs DA, Dunn JP, et al. The eye in bone marrow transplant. Arch Ophthalmol. 1994;112:372-379.
24. Perren BA, Raisanen J, Good WV, Crawford JB. Cytomegalovirus retinitis and optic neuritis in a severe combined immunodeficiency syndrome. Retina. 1996;16:117-121.
25. Suzuki N, Kudoh T, Mizue N, et al. CMV retinitis after cessation of ganciclovir therapy for CMV antigenemia in an unrelated BMT recipient. Bone Marrow Transplant. 1998;22:931-932.
26. Macdonald JC, Torriani FJ, Morse LS, Karavellas MP, Reed JB, Freeman WR. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. 1998;177: 1182-1187.
27. van den Horn GJ, Meenken C, Danner SA, Reiss P, de Smet MD. Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte response in HIV+ patients. Br J Ophthalmol. 1998;82:988-990.
28. Lange H, Muller TF, Ebel H, et al. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl Int. 1999;12:2-9.
29. Bacigalupo A, Tedone E, Van Lint MT, et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of development CMV infections. Bone Marrow Transplant. 1994;13:783-788.